Journal
RSC ADVANCES
Volume 6, Issue 52, Pages 46356-46365Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/c6ra07356e
Keywords
-
Categories
Funding
- National Natural Science Foundation of China [81172932, 81273376]
- Natural Science Foundation of Jiangsu Province [BK2012356]
- Fundamental Research Funds for the Central Universities, China Pharmaceutical University [JKZD2013001]
Ask authors/readers for more resources
The free fatty acid receptor 1 (FFA1) plays a key role in amplifying glucose-stimulated insulin secretion in pancreatic beta-cells. Most of the reported FFA1 agonists contain a biphenyl scaffold, which is associated with toxicity as verified by Daiichi Sankyo. Herein, we describe the systematic exploration of a non-biphenyl scaffold to improve the druggability of GW9508 (beta-oxidation, F-sp3 = 0.13, tPSA = 58.5 angstrom(2) directed by F-sp3 and tPSA values. All these optimizations ultimately led to the identification of compound 21, an unconventional agonist (EC50 = 72.5 nM) bearing a methyl oxime ether scaffold. Moreover, compound 21 revealed improved drug-like properties (F-sp3 = 0.23, tPSA = 86.6 angstrom(2)) when compared to GW9508 (F-sp3 = 0.13, tPSA = 58.5 angstrom(2) and an even higher binding efficiency index (BEI = 15.3) than TAK-875 (BEI = 14.3). Further pharmacological studies suggested that compound 21 has a considerable hypoglycemic effect in both normal and type 2 diabetic mice with a low risk of hypoglycemia. In addition, the docking study promoted our understanding of the ligand-binding pocket. This information might help towards the design of more promising new molecular entities.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available